Paper40908522
Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches.
Wal A and 6 others. Cardiovasc Hematol Disord Drug Targets, 2026. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches. Papers, record 40908522. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40908522
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Therapeutic Targets for Myocardial Fibrosis: A Comprehensive Review of Current and Emerging Approaches.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Myocardium | Major topic |
| Cardiomyopathies | Major topic |
| Cardiovascular Diseases | Major topic |
| Humans | |
| Fibrosis | |
| Animals | |
| Molecular Targeted Therapy |
Source PubMed
References202
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 32317975 | Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32317975 | PubMed |
| 2 | 33501848 | Heart Disease and Stroke Statistics-2021 Update: A Report From the American Heart Association. | Circulation | 2021 | https://conductscience.org/library/papers/33501848 | PubMed |
| 3 | 28157267 | Myocardial fibrosis: biomedical research from bench to bedside. | Eur J Heart Fail | 2017 | https://conductscience.org/library/papers/28157267 | PubMed |
| 4 | 32862327 | Myocardial Fibrosis in Heart Failure: Anti-Fibrotic Therapies and the Role of Cardiovascular Magnetic Resonance in Drug Trials. | Cardiol Ther | 2020 | https://conductscience.org/library/papers/32862327 | PubMed |
| 5 | 33014530 | Roles of Biomarkers in Myocardial Fibrosis. | Aging Dis | 2020 | https://conductscience.org/library/papers/33014530 | PubMed |
| 6 | 32955172 | Targeting cardiac fibrosis in heart failure with preserved ejection fraction: mirage or miracle? | EMBO Mol Med | 2020 | https://conductscience.org/library/papers/32955172 | PubMed |
| 7 | 28565750 | Myocardial fibrosis in congenital and pediatric heart disease. | Exp Ther Med | 2017 | https://conductscience.org/library/papers/28565750 | PubMed |
| 8 | 36247487 | Detection of myocardial fibrosis: Where we stand. | Front Cardiovasc Med | 2022 | https://conductscience.org/library/papers/36247487 | PubMed |
| 9 | 33135058 | Cardiac fibrosis. | Cardiovasc Res | 2021 | https://conductscience.org/library/papers/33135058 | PubMed |
| 10 | 36675283 | Signaling Pathways and Potential Therapeutic Strategies in Cardiac Fibrosis. | Int J Mol Sci | 2023 | https://conductscience.org/library/papers/36675283 | PubMed |
| 11 | 36979345 | Diffuse Myocardial Fibrosis on Cardiac Magnetic Resonance Imaging Is Related to Galectin-3 and Predicts Outcome in Heart Failure. | Biomolecules | 2023 | https://conductscience.org/library/papers/36979345 | PubMed |
| 12 | 31542534 | Myocardial Tissue Characterization and Fibrosis by Imaging. | JACC Cardiovasc Imaging | 2020 | https://conductscience.org/library/papers/31542534 | PubMed |
| 13 | 36221014 | Treatment of cardiac fibrosis: from neuro-hormonal inhibitors to CAR-T cell therapy. | Heart Fail Rev | 2023 | https://conductscience.org/library/papers/36221014 | PubMed |
| 14 | 31158407 | Cardiac fibrosis - A short review of causes and therapeutic strategies. | Adv Drug Deliv Rev | 2019 | https://conductscience.org/library/papers/31158407 | PubMed |
| 15 | 37504569 | Bioactive Compounds and Cardiac Fibrosis: Current Insight and Future Prospect. | J Cardiovasc Dev Dis | 2023 | https://conductscience.org/library/papers/37504569 | PubMed |
| 16 | 27226899 | Antifibrotic therapies to control cardiac fibrosis. | Biomater Res | 2016 | https://conductscience.org/library/papers/27226899 | PubMed |
| 17 | 29293097 | Resolution of organ fibrosis. | J Clin Invest | 2018 | https://conductscience.org/library/papers/29293097 | PubMed |
| 18 | 29155002 | PDGF in organ fibrosis. | Mol Aspects Med | 2018 | https://conductscience.org/library/papers/29155002 | PubMed |
| 19 | 30540232 | Mechanisms for the Resolution of Organ Fibrosis. | Physiology (Bethesda) | 2019 | https://conductscience.org/library/papers/30540232 | PubMed |
| 20 | 36140279 | Novel Therapies for the Treatment of Cardiac Fibrosis Following Myocardial Infarction. | Biomedicines | 2022 | https://conductscience.org/library/papers/36140279 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| TGFB1 | 7040 | PubTator's text mining | https://conductscience.org/library/genes/7040 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40908522
GET https://conductscience.org/api/papers/v1/40908522/references?page=2